These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37023366)

  • 1. iMSEA: A Novel Metabolite Set Enrichment Analysis Strategy to Decipher Drug Interactions.
    Wang Y; Liu X; Dong L; Cheng KK; Lin C; Wang X; Dong J; Deng L; Raftery D
    Anal Chem; 2023 Apr; 95(15):6203-6211. PubMed ID: 37023366
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Lin C; Dong J; Wei Z; Cheng KK; Li J; You S; Liu Y; Wang X; Chen Z
    J Proteome Res; 2020 Feb; 19(2):781-793. PubMed ID: 31916767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
    Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
    NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Correlations Informed Metabolite Set Enrichment Analysis to Decipher Metabolic Heterogeneity of Disease.
    Lin G; Dong L; Cheng KK; Xu X; Wang Y; Deng L; Raftery D; Dong J
    Anal Chem; 2023 Aug; 95(33):12505-12513. PubMed ID: 37557184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparse PLS-Based Method for Overlapping Metabolite Set Enrichment Analysis.
    Deng L; Ma L; Cheng KK; Xu X; Raftery D; Dong J
    J Proteome Res; 2021 Jun; 20(6):3204-3213. PubMed ID: 34002606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
    De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
    Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.
    Zhou R; Wu K; Su M; Li R
    Environ Toxicol Pharmacol; 2019 Aug; 70():103200. PubMed ID: 31158732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacology.
    Jiang J; Yang Z; Hou G; Yao X; Jiang J
    Ann Hepatol; 2022; 27(4):100701. PubMed ID: 35351639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
    Mou T; Zhu D; Wei X; Li T; Zheng D; Pu J; Guo Z; Wu Z
    World J Surg Oncol; 2017 Mar; 15(1):63. PubMed ID: 28302149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Key Functional Modules and Immunomodulatory Regulators of Hepatocellular Carcinoma.
    Luo D; Zhang X; Li XK; Chen G
    J Immunol Res; 2021; 2021():1801873. PubMed ID: 34423049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
    Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
    Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Metabolomic Analysis Reveals Dynamic Metabolic Reprogramming in Hep3B Cells with Aflatoxin B1 Exposure.
    Wang S; Yang X; Liu F; Wang X; Zhang X; He K; Wang H
    Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34072178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.
    Wang LL; Liao C; Li XQ; Dai R; Ren QW; Shi HL; Wang XP; Feng XS; Chao X
    Med Sci Monit; 2021 Jan; 27():e927624. PubMed ID: 33436534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.
    Zheng JF; Lu J; Wang XZ; Guo WH; Zhang JX
    Med Sci Monit; 2015 Jun; 21():1781-91. PubMed ID: 26092946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism of
    Hu Y; Yang L; Lu Y; Wang Y; Jiang J; Liu Y; Cao Q
    Evid Based Complement Alternat Med; 2022; 2022():2116006. PubMed ID: 36193154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated spatially resolved metabolomics and network toxicology to investigate the hepatotoxicity mechanisms of component D of Polygonum multiflorum Thunb.
    Jiang HY; Gao HY; Li J; Zhou TY; Wang ST; Yang JB; Hao RR; Pang F; Wei F; Liu ZG; Kuang L; Ma SC; He JM; Jin HT
    J Ethnopharmacol; 2022 Nov; 298():115630. PubMed ID: 35987407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urine metabolomics study of hepatocellular carcinoma].
    Xie XF; Sun Y; Zhao XH
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):252-259. PubMed ID: 35316875
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell metabolomics study on synergistic anti-hepatocellular carcinoma effect of Aidi injection combined with doxorubicin.
    Wang Y; Zhu X; Wang K; Cai Y; Liu C; Pan J; Sun J; Liu T; Huang Y; Li Y; Lu Y
    Biomed Chromatogr; 2022 Oct; 36(10):e5451. PubMed ID: 35848595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis.
    He B; Yin J; Gong S; Gu J; Xiao J; Shi W; Ding W; He Y
    Medicine (Baltimore); 2017 Jun; 96(25):e6938. PubMed ID: 28640074
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.